conivaptan has been researched along with telmisartan in 4 studies
| Studies (conivaptan) | Trials (conivaptan) | Recent Studies (post-2010) (conivaptan) | Studies (telmisartan) | Trials (telmisartan) | Recent Studies (post-2010) (telmisartan) |
|---|---|---|---|---|---|
| 188 | 17 | 64 | 1,930 | 480 | 1,038 |
| Protein | Taxonomy | conivaptan (IC50) | telmisartan (IC50) |
|---|---|---|---|
| Cytochrome P450 2C9 | Homo sapiens (human) | 0.42 | |
| Type-1 angiotensin II receptor | Homo sapiens (human) | 0.0179 | |
| Type-2 angiotensin II receptor | Homo sapiens (human) | 0.0003 | |
| Cytochrome P450 2J2 | Homo sapiens (human) | 0.5 | |
| Solute carrier organic anion transporter family member 1B3 | Homo sapiens (human) | 1.2589 | |
| Solute carrier organic anion transporter family member 1B1 | Homo sapiens (human) | 1.8621 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Mowrey, DD; Sun, T; Tang, P; Tillman, TS; Wells, MM; Xu, Y | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
1 review(s) available for conivaptan and telmisartan
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
3 other study(ies) available for conivaptan and telmisartan
| Article | Year |
|---|---|
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Ensemble-based virtual screening for cannabinoid-like potentiators of the human glycine receptor α1 for the treatment of pain.
Topics: Analgesics, Non-Narcotic; Animals; Binding Sites; Cannabinoids; Drug Evaluation, Preclinical; Female; Lipids; Molecular Dynamics Simulation; Molecular Targeted Therapy; Nuclear Magnetic Resonance, Biomolecular; Oocytes; Pain; Protein Conformation; Protein Structure, Tertiary; Receptors, Glycine; Reproducibility of Results; Xenopus laevis | 2015 |